-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Original: The White WordNovember 6, Qilu Pharmaceuticals two heavy-duty generic drugs were approved for the market, respectively, injection with yew alcohol (albumin binding type) and he Darafi tabletsSince all are registered in accordance with the 4 categories, approved as the same as through the consistency evaluation, so that these two heavyweight varieties in the domestic through the consistency evaluation of imitation enterprises have reached 3, injection with sequoia (albumin binding type)albumin yew alcohol developed by the United States Abraxis BioScience, is a new preparation combined with albumin, to overcome the common yew alcohol water solubility, low efficiency and side effects, etc, in January 2005 was approved by the FDA for treatment of breast cancer (commodity name Abraxe), and then approved for treatment of lung cancer, pancreatic cancerIn 2010, The new base acquired Abraxis for a down payment of $2.9 billion, pocketing Abraxane's revenueIn 2018, Abraxane's global sales will be approximately $1,062 millionAbraxane was approved in China in 2008/6/10In July 2017, Baiji Shenzhou acquired Abraxane's commercial rights in China through a deal with CelgeneQilu is the third domestic enterprise to obtain the listing qualification of the generic drug of this variety after Shi medicine and HengruiIn addition, Haizheng, Collum and Kangyu Biological and other enterprises of albumin yew alcohol listing application is also in the "review" stage
from the median price of the winning bid, the new base, stone medicine and Hengrui, respectively, 5510, 2680 and 3280 yuan (100mg)It is worth noting that the new base has achieved a number of price reductions in Jiangsu, Shandong and other places of the latest winning bid price of 3350 yuan (100mg)source: PharmaGo winning database of the pharmaceutical rubula
II, TadalafiTadalafi is a selective, reversible diesterase 5 (PDE5) inhibitor, the original manufacturer of Lilly The drug used to address the male erectile dysfunction (ED) indications and the West Dalafi, fadina non-difference is that the efficacy of tadallafi lasts up to 36 hours, much longer than the last two 3-4 hours of efficacy duration, reducing the patient's concerns about the length of time of the drug In addition, hedarafi has been approved for the treatment of benign prostate hyperplasia and pulmonary hypertension Lilly introduced a daily 5 mg dose of oral tadalafi on the basis of long-acting PDE5 inhibitors, revolutionizing a new model of male ED treatment that completely freed patients from taking the drug, and gradually lowered his market share of ED drugs and outplayed the much-known Viagra (West Nida) , Hedarafi Wason research was listed in China in November 2004, once a day 5mg small specifications are listed in China in December 2013, has now lost patent protection in China Qilu is the third domestic enterprise to obtain the listing of the generic drug after Changchun Haiyue and Nanjing Zhengda According to the PharmaGo database of the pharmaceutical rub, the variety has been approved for listing of the three manufacturers, including Hengrui, DongSunyan, including 13 enterprises in accordance with the new category 4 declaration In addition, five companies develop oral fluids and oral instant films.